These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 9342326)

  • 1. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa.
    Pipe SW; Kaufman RJ
    Proc Natl Acad Sci U S A; 1997 Oct; 94(22):11851-6. PubMed ID: 9342326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.
    Gale AJ; Radtke KP; Cunningham MA; Chamberlain D; Pellequer JL; Griffin JH
    J Thromb Haemost; 2006 Jun; 4(6):1315-22. PubMed ID: 16706977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo.
    Pipe SW; Eickhorst AN; McKinley SH; Saenko EL; Kaufman RJ
    Blood; 1999 Jan; 93(1):176-83. PubMed ID: 9864159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
    Saenko EL; Shima M; Gilbert GE; Scandella D
    J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining mutations that modulate inter-subunit interactions and proteolytic inactivation enhance the stability of factor VIIIa.
    Wakabayashi H; Wintermute JM; Fay PJ
    Thromb Haemost; 2014 Jul; 112(1):43-52. PubMed ID: 24599523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa.
    Gale AJ; Pellequer JL
    J Thromb Haemost; 2003 Sep; 1(9):1966-71. PubMed ID: 12941038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa.
    Pipe SW; Saenko EL; Eickhorst AN; Kemball-Cook G; Kaufman RJ
    Blood; 2001 Feb; 97(3):685-91. PubMed ID: 11157485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin-activated and factor Xa-activated human factor VIII: differences in cofactor activity and decay rate.
    Neuenschwander PF; Jesty J
    Arch Biochem Biophys; 1992 Aug; 296(2):426-34. PubMed ID: 1632634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.
    Radtke KP; Griffin JH; Riceberg J; Gale AJ
    J Thromb Haemost; 2007 Jan; 5(1):102-8. PubMed ID: 17059431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and functional characterization of platelet receptor-mediated factor VIII binding.
    Ahmad SS; Scandura JM; Walsh PN
    J Biol Chem; 2000 Apr; 275(17):13071-81. PubMed ID: 10777612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets.
    Saenko EL; Scandella D; Yakhyaev AV; Greco NJ
    J Biol Chem; 1998 Oct; 273(43):27918-26. PubMed ID: 9774404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacing the factor VIII C1 domain with a second C2 domain reduces factor VIII stability and affinity for factor IXa.
    Wakabayashi H; Fay PJ
    J Biol Chem; 2013 Oct; 288(43):31289-97. PubMed ID: 24030831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of an antibody specific for coagulation factor VIII that enhances factor VIII activity.
    Takeyama M; Nogami K; Matsumoto T; Soeda T; Suzuki T; Hattori K; Shima M
    Thromb Haemost; 2010 Jan; 103(1):94-102. PubMed ID: 20062922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acidic Region Residues 1680-1684 in the A3 Domain of Factor VIII Contain a Thrombin-Interactive Site Responsible for Proteolytic Cleavage at Arg1689.
    Nakajima Y; Minami H; Nogami K
    Thromb Haemost; 2021 Oct; 121(10):1274-1288. PubMed ID: 33592631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of factor VIII light-chain residues 2007-2016 to an activated protein C-interactive site.
    Takeyama M; Wakabayashi H; Fay PJ
    Thromb Haemost; 2013 Feb; 109(2):187-98. PubMed ID: 23224054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cofactor activity in factor VIIIa of the blood clotting pathway is stabilized by an interdomain bond between His281 and Ser524 formed in factor VIII.
    Wakabayashi H; Monaghan M; Fay PJ
    J Biol Chem; 2014 May; 289(20):14020-9. PubMed ID: 24692542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin.
    Hill-Eubanks DC; Parker CG; Lollar P
    Proc Natl Acad Sci U S A; 1989 Sep; 86(17):6508-12. PubMed ID: 2505252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation.
    Parker ET; Lollar P
    Biochemistry; 2007 Aug; 46(34):9737-42. PubMed ID: 17676877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin G, a leukocyte protease, activates coagulation factor VIII.
    Gale AJ; Rozenshteyn D
    Thromb Haemost; 2008 Jan; 99(1):44-51. PubMed ID: 18217133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of human neutrophil elastase-catalysed inactivation of factor VIII(a).
    Nogami K; Ogiwara K; Matsumoto T; Nishiya K; Takeyama M; Shima M
    Thromb Haemost; 2011 Jun; 105(6):968-80. PubMed ID: 21475777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.